Upgrade to SI Premium - Free Trial

Teva Pharma (TEVA): Concerns on Generics Overdone - Guggenheim

November 15, 2016 10:26 AM
Guggenheim analyst Louise Chen reiterated a Buy rating and $80 price target on Teva Pharma (NYSE: TEVA) following results ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Analyst EPS View

Next Articles